Literature DB >> 2159693

Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors.

T Unger1, P Gohlke.   

Abstract

The existence of independently functioning local renin-angiotensin systems in a number of tissues has been firmly established by biochemical and functional evidence and, most recently, by the demonstration of genetic messages for components of the renin-angiotensin systems, such as renin and angiotensinogen, in several organs. In this review, local renin-angiotensin systems in the heart and vascular walls are described and the contribution of a local inhibition of converting enzymes to the cardiovascular actions of converting enzyme inhibitors is discussed. Most of the studies cited support the hypothesis that an inhibition of cardiac converting enzyme may be involved in the beneficial hemodynamic and metabolic actions of converting enzyme inhibitors in cardiovascular disease, such as hypertension and congestive heart failure, independent of the circulating renin-angiotensin system. Local effects on cardiac converting enzyme may contribute to the ability of converting enzyme inhibitors to reduce cardiac hypertrophy. Similarly, local converting enzyme inhibition in the vascular wall may not only constitute a mechanism involved in the antihypertensive effects of converting enzyme inhibitors, but may also contribute to the regression of hypertension-induced vascular hypertrophy. In addition to reduced local angiotensin II generation, converting enzyme inhibition may engender a potentiation of the local effects of kinins. This mechanism may be more important to the cardiovascular actions of converting enzyme inhibitors than initially thought.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159693     DOI: 10.1016/0002-9149(90)90118-k

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans.

Authors:  G H Goossens; S E McQuaid; A L Dennis; M A van Baak; E E Blaak; K N Frayn; W H M Saris; F Karpe
Journal:  J Physiol       Date:  2006-01-05       Impact factor: 5.182

2.  Expression of renin and angiotensin-converting enzyme in human hearts.

Authors:  Y Endo-Mochizuki; N Mochizuki; H Sawa; A Takada; H Okamoto; H Kawaguchi; K Nagashima; A Kitabatake
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

3.  Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis.

Authors:  D A Walsh; J Catravas; J Wharton
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

Review 4.  Nitric oxide and cardioprotection during ischemia-reperfusion.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

5.  Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values.

Authors:  Aldo S Villecco; Cinzia Cocci; Maurizio Di Emidio
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

6.  Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.

Authors:  Jaclyn H Neo; Eleanor I Ager; Peter W Angus; Jin Zhu; Chandana B Herath; Christopher Christophi
Journal:  BMC Cancer       Date:  2010-04-10       Impact factor: 4.430

7.  Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.

Authors:  C Rangemark; H Lind; L Lindholm; T Hedner; O Samuelsson
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

8.  The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.

Authors:  Gary L Schwartz; Kent Bailey; Arlene B Chapman; Eric Boerwinkle; Stephen T Turner
Journal:  Am J Hypertens       Date:  2013-04-16       Impact factor: 2.689

Review 9.  ACE-inhibitors and atherosclerosis.

Authors:  E Ambrosioni; S Bacchelli; D Degli Esposti; C Borghi
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 10.  Nitric oxide and cardiovascular protection.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.